NCT07887984
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (17)
Show 12 moreShow less
Arms and interventions
INDUCTION: Patients receive the DaraRVd regimen consisting of: 1) daratumumab and recombinant human hyaluronidase SC on days 1, 8, and 15 of each cycle; 2) lenalidomide PO on days 1-14 of each cycle; 3) bortezomib SC on days 1, 4, 8, and 11 of each cycle; and 4) dexamethasone PO or IV on days 1, 4, 8, 11, and 15 of each cycle. Cycles repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients undergo ASCT and receive melphalan IV on a single day or on two consecutive days. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days for 26 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.
INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive teclistamab SC on days 1, 4, 8, and 15 of cycle 1 and then on days 1 and 15 of cycles thereafter. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.
INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive talquetamab SC on days 1, 4, 8, and 15 of cycle 1 and then on days 1 and 15 of cycles thereafter. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.
INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive teclistamab SC and talquetamab SC on days 1, 4, 8, and 15 of cycle 1 and then on days 1 and 15 of cycles thereafter. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.
INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients undergo ASCT and receive melphalan as in Phase II Arm 1. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.
INDUCTION: Patients receive the DaraRVd regimen as in Phase II Arm 1. CONSOLIDATION: Patients receive teclistamab alone as in Phase II Arm 2, talquetamab alone as in Phase II Arm 3, or teclistamab and talquetamab together as in Phase II Arm 4. MAINTENANCE: Patients receive daratumumab and recombinant human hyaluronidase and lenalidomide as in Phase II Arm 1. Patients also undergo PET/CT, collection of blood, and bone marrow aspiration/biopsy throughout the study. Patients may also undergo MRI on study.
Drugs: Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib, Dexamethasone, Melphalan, Teclistamab
Procedures: Autologous Hematopoietic Stem Cell Transplantation, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Magnetic Resonance Imaging
Biologicals: Talquetamab